The short version of GW501516 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
===== Senate report (October 2005) ===== The report, by the then-majority Republican Party staff of the Senate committee, was published in October 2005. It stated that Galloway had "knowingly made false or misleading statements under oath". The report exhibits bank statements, which the authors claim show that $150,000 of proceeds from the Oil-for-Food Program had been paid to Galloway's wife Amineh Abu-Zayyad. It also stated that Galloway (and the Mariam Appeal) received eight allocations of oil from the Iraqi government amounting to 23 million barrels from 1999 to 2003. The Mariam Appeal was also found to have improperly received $446,000 via the Oil-for-Food Program. Iraq's former prime minister Tariq Aziz was said to have told the investigators that oil had been allocated in the names of two of Galloway's representatives: Buhan Al-Chalabi and Fawaz Zureikat. Aziz had told the investigators: "These oil allocations were for the benefit of George Galloway and for Mariam's Appeal. The proceeds from the sale benefited the cause and Mr Galloway". Galloway reiterated his denial of the charges and asked the US Senate committee to charge him with perjury so that he could confront the charges in court. He said the investigation was an attempt to divert attention from the "pack of lies" that led to the Iraq invasion in 2003. He said Coleman's motive was revenge over the embarrassment of his appearance before the committee in May. Galloway also said he spoke to Aziz's lawyers, who told him "Tariq Aziz absolutely denies ever saying that I benefited from oil deals".
3,4-Dihydroxyphenylacetic acid (DOPAC) is a metabolite of the neurotransmitter dopamine. Dopamine can be metabolized into one of three substances. One such substance is DOPAC. Another is 3-methoxytyramine (3-MT). Both of these substances are degraded to form homovanillic acid (HVA). Both degradations involve the enzymes monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT), albeit in reverse order: MAO catalyzes dopamine to DOPAC, and COMT catalyzes DOPAC to HVA; whereas COMT catalyzes dopamine to 3-MT and MAO catalyzes 3-MT to HVA. The third metabolic end-product of dopamine is norepinephrine (noradrenaline).
=== Muscle biopsy === If DNA testing fails to find the mutation, a muscle biopsy test may be performed. A small sample of muscle tissue is extracted using a biopsy needle. The key tests performed on the biopsy sample for Duchenne muscular dystrophy are immunohistochemistry, immunocytochemistry, and immunoblotting for dystrophin, and should be interpreted by an experienced neuromuscular pathologist. These tests provide information on the presence or absence of the protein. Absence of the protein is a positive test for Duchenne muscular dystrophy. Where dystrophin is present, the tests indicate the amount and molecular size of dystrophin, helping to distinguish Duchenne muscular dystrophy from milder dystrophinopathy phenotypes. Over the past several years, DNA tests have been developed that detect more of the many mutations that cause the condition, and muscle biopsy is not required as often to confirm the presence of Duchenne muscular dystrophy.
Sources: en.wikipedia.org
=== Pusha T's solo career and work relationship with GOOD Music === Before releasing any solo material, Pusha T signed in the autumn of 2010 to GOOD Music, a record label founded by West. That year, he appeared on multiple songs in West's GOOD Fridays series, rapped in the GOOD cypher at the BET Hip Hop Awards, and had two features on West's album My Beautiful Dark Twisted Fantasy. The creative partnership was fruitful; Pusha T became president of GOOD in 2015, and West had production credits on all of his commercially released albums until It's Almost Dry. Pusha T was publicly outspoken about not seeing eye-to-eye with West on politics and career moves multiple times. Among other examples, he expressed disagreement over West's support of Donald Trump and claimed to have different principles on music industry relationships. The relationship had completely deteriorated by late 2022, after West made statements widely condemned as antisemitic. Pusha T said the following in response to West's comments: "It's definitely affected me. It's been disappointing. As a Black man in America, there is no room for bigotry or hate speech. So yeah. It's been very disappointing, let's talk straight." In another interview, he said: "It's beyond [wild stuff] and it's nothing to tap dance around. It's wrong. Period." and "He's not speaking to me now. If you ain't with it, you ain't down. And I ain't with it. I'm not budging on that. I'm not with it." He also clarified that he was no longer the president of GOOD or affiliated with the label in any way.
Its half-life must be long enough so that it will release energy at a relatively constant rate for a reasonable amount of time. The amount of energy released per time (power) of a given quantity is inversely proportional to half-life. An isotope with twice the half-life and the same energy per decay will release power at half the rate per mole. Typical half-lives for radioisotopes used in RTGs are therefore several decades, although isotopes with shorter half-lives could be used for specialized applications. For spaceflight use, the fuel must produce a large amount of power per mass and volume (density). Density and weight are not as important for terrestrial use, unless there are size restrictions. The decay energy can be calculated if the energy of radioactive radiation or the mass loss before and after radioactive decay is known. Energy release per decay is proportional to power production per mole. Radiation must be of a type easily absorbed and transformed into thermal radiation, preferably alpha radiation. Beta radiation can emit considerable gamma/X-ray radiation through bremsstrahlung secondary radiation production and therefore requires heavy shielding. Isotopes must not produce significant amounts of gamma, neutron radiation or penetrating radiation in general through other decay modes or decay chain products. The first two criteria limit the number of possible fuels to fewer than thirty nuclides within the entire table of nuclides.
Conversely, with some other catalysts, ethylene oxide may be reduced by hydrogen to ethylene with the yield up to 70%. The reduction catalysts include mixtures of zinc dust and acetic acid, of lithium aluminium hydride with titanium trichloride (the reducing agent is actually titanium dichloride, formed by the reaction between LiAlH4 and TiCl3) and of iron(III) chloride with butyllithium in tetrahydrofuran.
Sources: en.wikipedia.org
Interest in a possible island of stability grew throughout the 1960s, as some calculations suggested that it might contain nuclides with half-lives of billions of years. They were also predicted to be especially stable against spontaneous fission in spite of their high atomic mass. It was thought that if such elements exist and are sufficiently long-lived, there may be several novel applications as a consequence of their nuclear and chemical properties. These include use in particle accelerators as neutron sources, in nuclear weapons as a consequence of their predicted low critical masses and high number of neutrons emitted per fission, and as nuclear fuel to power space missions. These speculations led many researchers to conduct searches for superheavy elements in the 1960s and 1970s, both in nature and through nucleosynthesis in particle accelerators. During the 1970s, many searches for long-lived superheavy nuclei were conducted. Experiments aimed at synthesizing elements ranging in atomic number from 110 to 127 were conducted at laboratories around the world. These elements were sought in fusion-evaporation reactions, in which a heavy target made of one nuclide is irradiated by accelerated ions of another in a cyclotron, and new nuclides are produced after these nuclei fuse and the resulting excited system releases energy by evaporating several particles (usually protons, neutrons, or alpha particles).
=== Piast monarchy under Casimir I, Bolesław II and Bolesław III === Bolesław I's expansive rule overstretched the resources of the early Polish state, and it was followed by a collapse of the monarchy. Recovery took place under Casimir I the Restorer (r. 1039–1058). Casimir's son Bolesław II the Generous (r. 1058–1079) became involved in a conflict with Bishop Stanislaus of Szczepanów that ultimately caused his downfall. Bolesław had the bishop murdered in 1079 after being excommunicated by the Polish church on charges of adultery. This act sparked a revolt of Polish nobles that led to Bolesław's deposition and expulsion from the country. Around 1116, Gallus Anonymus wrote a seminal chronicle, the Gesta principum Polonorum, intended as a glorification of his patron Bolesław III Wrymouth (r. 1107–1138), a ruler who revived the tradition of military prowess of Bolesław I's time. Gallus' work remains a paramount written source for the early history of Poland.
=== Critical response === On Rotten Tomatoes, the film has an approval rating of 18% based on 50 reviews, with an average of 3.4/10. The website's critical consensus reads, "An action thriller starring Mads Mikkelsen as the world's most dangerous assassin should be terrifically entertaining, but Polar proves it's possible to ruin anything if you try." On Metacritic, the film has a weighted average score of 19 out of 100, based on reviews from 12 critics, indicating "overwhelming dislike".
== History == Generate:Biomedicines was founded in 2018 by Flagship Pioneering. The company was established to develop a data-driven approach to understanding the relationship between protein sequence and function with the aim of creating novel proteins for therapeutic purposes. The company operated in stealth mode until its public unveiling on September 10, 2020. At that time, Generate announced its focus on using machine learning algorithms and big data to design biological compounds targeting multiple diseases, including SARS-CoV-2, the virus causing COVID-19. Its computational platform integrated vast datasets of protein structures and genetic sequences to develop governing rules for designing new proteins. In March 2021, Mike Nally, formerly of Merck, joined as chief executive officer to advance the company's technology and operational capabilities. Under his leadership, Generate expanded its infrastructure and initiated multiple strategic collaborations. By 2023, Generate had raised financing, including a $273 million Series C round, the largest biotech Series C of the year. These funds supported the company's first-in-human clinical trial for GB-0669, a monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike protein, and its pipeline of 17 programs spanning immunology, infectious disease, and oncology. In September 2024, Generate secured a partnership with Novartis, potentially worth over $1 billion, to leverage its generative artificial intelligence (AI) platform for the development of protein therapeutics.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.